Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension

Bibliography

• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-72
   PubMed Web of Science ®Google Scholar
• Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001;161(22):2661-7
   Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159-219
   PubMed Web of Science ®Google Scholar
• Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 2009;53(5):379-87
   PubMed Web of Science ®Google Scholar
• Skeberdis VA. Structure and function of beta3-adrenergic receptors. Medicina (Kaunas) 2004;40(5):407-13
   PubMedGoogle Scholar
• Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54(16):1491-9
   PubMed Web of Science ®Google Scholar
• Ma L, Gul R, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol 2012;302(11):H2341-51
   Google Scholar
• de Groot AA, Mathy MJ, Van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43(1):148-53
   PubMed Web of Science ®Google Scholar
• Mason RP, Kubant R, Jacob RF, et al. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 2006;48(1):862-9
   PubMed Web of Science ®Google Scholar
• Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003;92(3):344-8
   PubMed Web of Science ®Google Scholar
• Dhakam Z, Yasmin McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26(2):351-6; 13
   PubMed Web of Science ®Google Scholar
• Carella AM, Antonucci G, Conte M, et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 2010;6(4):215-21
   PubMedGoogle Scholar
• Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 2014;383(9932):1889-98
   PubMed Web of Science ®Google Scholar
• Waeber B, Feihl F. Nebivolol and valsartan: useful treatment for hypertension? Lancet 2014;383(9932):1864-6
   PubMed Web of Science ®Google Scholar
• Tomlinson LA, Selvarajah V, Wilkinson IB. Rate-limiting step: can different effects of antihypertensives on central blood pressure be translated into outcomes? Hypertension 2011;57(6):1047-8
   PubMed Web of Science ®Google Scholar
• Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011;57(6):1122-8
   PubMed Web of Science ®Google Scholar
• Polonia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with beta-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit 2010;15(5):235-9
   Google Scholar
• Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014;8(2):74-82
   PubMed Web of Science ®Google Scholar
• Nodari S, Metra M, Dei CL. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long- term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5(5):621-7
   PubMed Web of Science ®Google Scholar
• Brehm BR, Wolf SC, Gorner S, et al. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002;4(6):757-63
   PubMed Web of Science ®Google Scholar
• Lombardo RM, Reina C, Abrignani MG, et al. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs 2006;6(4):259-63
   PubMedGoogle Scholar
• Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005;7(4):631-9
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. Eur Heart J 2005;26(3):215-25
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. developed in collaboration with the heart failure association of the ESC (HEART FAILUREA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29(19):2388-442
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HEART FAILUREA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10(10):933-89
   PubMed Web of Science ®Google Scholar
• Cohn JN. Improving outcomes in congestive heart failure: val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999;91(Suppl 1):19-22
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906
   PubMed Web of Science ®Google Scholar
• Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27(5):562-8
   PubMed Web of Science ®Google Scholar
• Van Veldhuisen DJ, Cohen-Solal A, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure). J Am Coll Cardiol 2009;53(23):2150-8
   PubMed Web of Science ®Google Scholar
• Jessup M. The heart failure paradox: an epidemic of scientific success: presidential address at the american heart association 2013 scientific sessions. Circulation 2014;129(25):2717-22
   PubMed Web of Science ®Google Scholar
• Vinereanu D, Gherghinescu C, Ciobanu AO, et al. Reversal of subclinical left ventricular dysfunction by atntihypertensive treatment: a prospective trial of nebivolol against metoprolol. J Hypertens 2011;29(4):809-17
   PubMed Web of Science ®Google Scholar
• Zhou X, Ma L, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stressin the Zucker obese rat. Hypertension 2010;55(4):880-8
   PubMed Web of Science ®Google Scholar
• Varagic J, Ahmad S, Brosnihan KB, et al. Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. Am J Nephrol 2010;32(6):557-66
   PubMed Web of Science ®Google Scholar
• Varagic J, Ahmad S, Voncannon JL, et al. Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 2012;30(9):1766-74
   PubMed Web of Science ®Google Scholar
• Avci E, Yesil M, Bayata S, et al. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyol Derg 2011;11(7):613-17
   Google Scholar
• Gunebakmaz O, Kaya MG, Koc F, et al. Does nebivolol prevent contrast-induced nephropathy in humans? Clin Cardiol 2012;35(4):250-4
   PubMed Web of Science ®Google Scholar
• Duranay M, Kanbay M, Akay H, et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract 2010;114(3):c213-17
   PubMedGoogle Scholar
• Moniwa N, Varagic J, Ahmad S, et al. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension 2013;61(22):417-24
   Google Scholar